Back to Search
Start Over
A focus on the preclinical development and clinical status of the histone deacetylase inhibitor, romidepsin (depsipeptide, Istodax®)
- Source :
- Epigenomics
- Publication Year :
- 2012
- Publisher :
- Future Medicine Ltd, 2012.
-
Abstract
- Romidepsin (Istodax®, depsipeptide, FR901228, FK228, NSC 630176) is a cyclic peptide, broad-spectrum, potent histone deacetylase inhibitor, with activity mainly against class I histone deacetylase enzymes. In this article, we give an overview of the putative modes of action, such as effects on gene expression, cell cycle regulation, apoptosis induction, DNA repair, protein acetylation and induction of autophagy. Romidepsin has mainly been developed as a therapy for hematologic malignancies and is approved by the US FDA for the treatment of cutaneous T-cell lymphomas. This report outlines the laboratory and clinical development of the compound as a single agent that has more recently been evaluated in combination with other anticancer therapeutics, such as proteasome inhibitors.
- Subjects :
- Cancer Research
medicine.drug_class
Drug Evaluation, Preclinical
Antineoplastic Agents
Apoptosis
Biology
Pharmacology
Histone Deacetylase 6
Article
Histone Deacetylases
Romidepsin
Bortezomib
Cell Line, Tumor
Depsipeptides
Autophagy
Genetics
medicine
Animals
Humans
Depsipeptide
Clinical Trials as Topic
Neovascularization, Pathologic
Histone deacetylase inhibitor
Acetylation
Drug Synergism
HDAC6
Cell cycle
Hypoxia-Inducible Factor 1, alpha Subunit
Boronic Acids
Lymphoma, T-Cell, Cutaneous
Histone Deacetylase Inhibitors
Pyrazines
Cancer research
Histone deacetylase
Proteasome Inhibitors
medicine.drug
Subjects
Details
- ISSN :
- 1750192X and 17501911
- Volume :
- 4
- Database :
- OpenAIRE
- Journal :
- Epigenomics
- Accession number :
- edsair.doi.dedup.....3fb58d098e5020e2f066fd72bd6ab979